Diabetes Core Update cover image

Diabetes Core Update – February 2023

Diabetes Core Update

00:00

The Safety and Tolerability of a Novel Agent

The patients were recruited at four centers in the United States. Participants were randomly assigned to receive once weekly subcutaneous injections of the LY 343, 7943 or laglotide 1.5 milligram over a 12-week period. The emergent adverse effects were reported by 63%, 60% and 54% in the novel agent that did laglotide and the placebo respectively.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app